MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy

References

• Reid BM, Permuth JB, Sellers TA., et al. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;(4). DOI:10.1002/ijc.33588.
   Web of Science ®Google Scholar
• Yu L, Gong H, Li Q, et al. Survival analysis of radiation therapy in ovarian cancer: a SEER database analysis. J Oncol. 2021;2021:8849039.
   PubMed Web of Science ®Google Scholar
• Yang SD, Ahn SH, Kim JI., et al. 3-Oxoacid CoA transferase 1 as a therapeutic target gene for cisplatin-resistant ovarian cancer. Oncol Lett. 2018;15:2611–2618.
   PubMed Web of Science ®Google Scholar
• Zamarin D. Novel therapeutics: response and resistance in ovarian cancer. Int J Gynecol Cancer. 2019;29(Suppl 2):s16–s21.
   PubMedGoogle Scholar
• Zeller C, Brown R. Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. Ther Adv Med Oncol. 2010;2(5):319–329.
   PubMedGoogle Scholar
• Jing K, Lim K. Why is autophagy important in human diseases? Exp Mol Med. 2012;44(2):69–72.
   PubMed Web of Science ®Google Scholar
• Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27–42.
   PubMed Web of Science ®Google Scholar
• Wu WK, Coffelt SB, Cho CH, et al. The autophagic paradox in cancer therapy. Oncogene. 2012;31(8):939–953.
   PubMed Web of Science ®Google Scholar
• Du H, Yang W, Chen L, et al. Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma cells. Oncol Rep. 2012;27:143–150.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yang X, Zhao H, et al. Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer. Theranostics. 2018;8(19):5200–5212.
   PubMed Web of Science ®Google Scholar
• Hu Z, Cai M, Zhang Y, et al. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway. Cell Cycle. 2020;19(2):193–206.
   PubMed Web of Science ®Google Scholar
• Harrandah AM, Mora RA, Chan EKL., et al. Emerging microRNAs in cancer diagnosis, progression, and immune surveillance. Cancer Lett. 2018;438:126–132.
   PubMed Web of Science ®Google Scholar
• Chen W, Li Z, Liu H, et al. MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib. Cell Death Dis. 2020;11(3):198.
   PubMed Web of Science ®Google Scholar
• Lu W, He Y, Yu T, et al. Osthole down-regulates miR-30a and promotes autophagy to protect rats against myocardial ischemia/reperfusion injury. Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgery. 2019;27(2):178–184.
   Google Scholar
• Peng L, Ming Y, Zhang L, et al. MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway. Faseb J. 2020;34(4):5128–5143.
   PubMed Web of Science ®Google Scholar
• Du X, Liu B, Luan X, et al. miR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy. Exp Ther Med. 2018;15:599–605.
   PubMed Web of Science ®Google Scholar
• Wang LL, Zhang XH, Zhang X, et al. MiR-30a increases cisplatin sensitivity of gastric cancer cells through suppressing epithelial-to-mesenchymal transition (EMT). Eur Rev Med Pharmacol Sci. 2016;20:1733–1739.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang J, Liu Y, et al. MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells. BMC Cancer. 2018;18(1):404.
   PubMedGoogle Scholar
• Sestito R, Cianfrocca R, Rosanò L, et al. miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget. 2016;7(4):4009–4023.
   PubMed Web of Science ®Google Scholar
• Lin X, Lai X, Feng W, et al. MiR-30a sensitized lung cancer against neoadjuvant chemotherapy by depressing autophagy. Jpn J Clin Oncol. 2021;51(5):675–684.
   PubMed Web of Science ®Google Scholar
• Sarkhosh-Inanlou R, Molaparast M, Mohammadzadeh A, et al. Sanguinarine enhances cisplatin sensitivity via glutathione depletion in cisplatin-resistant ovarian cancer (A2780) cells. Chem Biol Drug Des. 2020;95(2):215–223.
   PubMed Web of Science ®Google Scholar
• He R, Wang M, Zhao C, et al. TFEB-driven autophagy potentiates TGF-β induced migration in pancreatic cancer cells. J Exp Clin Cancer Res. 2019;38(1):340.
   PubMed Web of Science ®Google Scholar
• Elies A, Rivière S, Pouget N, et al. The role of neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther. 2018;18(6):555–566.
   PubMed Web of Science ®Google Scholar
• Leidal AM, Levine B, Debnath J., et al. Autophagy and the cell biology of age-related disease. Nat Cell Biol. 2018;20(12):1338–1348.
   PubMed Web of Science ®Google Scholar
• Yan X, Zhou R, Ma Z., et al. Autophagy-cell survival and death. Adv Exp Med Biol. 2019;1206:667–696.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Han F, Yang S, et al. Oxamate-mediated inhibition of lactate dehydrogenase induces protective autophagy in gastric cancer cells: involvement of the Akt-mTOR signaling pathway. Cancer Lett. 2015;358(1):17–26.
   PubMed Web of Science ®Google Scholar
• Lv L, Liu HG, Dong SY, et al. Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells. Tumour Biol. 2016;37(7):8811–8824.
   PubMedGoogle Scholar
• Shi Y, Han Y, Xie F, et al. ASPP 2 enhances Oxaliplatin (L- OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy. J Cell Mol Med. 2015;19(3):535–543.
   PubMed Web of Science ®Google Scholar
• Sun Z, Shi K, Yang S, et al. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018;17(1):147.
   PubMed Web of Science ®Google Scholar
• Nam EJ, Kim S, Lee TS, et al. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue. Oncotarget. 2016;7(43):70524–70534.
   PubMedGoogle Scholar
• Li C, Zou J, Zheng G, et al. MiR-30a decreases multidrug resistance (MDR) of gastric cancer cells. Med Sci Monit. 2016;0:0.
   PubMedGoogle Scholar
• Meng F, Wang F, Wang L, et al. MiR-30a-5p overexpression may overcome EGFR-inhibitor resistance through regulating PI3K/AKT signaling pathway in non-small cell lung cancer cell lines. Front Genet. 2016;7:197.
   PubMed Web of Science ®Google Scholar
• Zhao M, Mishra L, Deng CX., et al. The role of TGF-β/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14(2):111–123.
   PubMed Web of Science ®Google Scholar